Trial watch: Self-inactivating gene-therapy vector alleviates safety concerns.
Megan
M
Cully
D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000592:standards*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics*; D006801:Humans; D007938:Leukemia / Q000139:chemically induced / Q000235:genetics; D012190:Retroviridae / Q000235:genetics*; D053632:X-Linked Combined Immunodeficiency Diseases / Q000235:genetics* / Q000628:therapy*